Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $11.56.

MRVI has been the topic of a number of recent analyst reports. Craig Hallum initiated coverage on shares of Maravai LifeSciences in a report on Wednesday. They issued a "buy" rating and a $15.00 price target on the stock. Stifel Nicolaus cut their price target on shares of Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 23rd. Finally, Royal Bank of Canada lifted their target price on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an "outperform" rating in a research note on Friday, February 23rd.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds have recently bought and sold shares of the business. Wedmont Private Capital boosted its stake in Maravai LifeSciences by 14.1% during the first quarter. Wedmont Private Capital now owns 42,439 shares of the company's stock worth $361,000 after acquiring an additional 5,242 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in Maravai LifeSciences during the first quarter worth about $187,000. Virtu Financial LLC bought a new stake in Maravai LifeSciences during the fourth quarter worth about $136,000. GSA Capital Partners LLP bought a new stake in Maravai LifeSciences during the fourth quarter worth about $320,000. Finally, Voloridge Investment Management LLC bought a new stake in Maravai LifeSciences during the fourth quarter worth about $2,571,000. Institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Trading Down 0.1 %

Maravai LifeSciences stock traded down $0.01 during trading hours on Thursday, reaching $8.59. The stock had a trading volume of 1,563,501 shares, compared to its average volume of 2,700,953. The stock has a market cap of $2.16 billion, a PE ratio of -9.54 and a beta of 0.01. Maravai LifeSciences has a 52 week low of $4.52 and a 52 week high of $16.62. The company has a debt-to-equity ratio of 0.70, a current ratio of 8.00 and a quick ratio of 7.41. The company has a fifty day simple moving average of $7.26 and a 200-day simple moving average of $6.82.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01). The firm had revenue of $74.14 million during the quarter, compared to the consensus estimate of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. Analysts forecast that Maravai LifeSciences will post -0.15 EPS for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.